The incidence of acute exacerbation did not reach statistical significance; however, the rate of acute exacerbations was lower in the reduced starting dosage group (3.6% vs. 12.1%).
← all excerpts
Clinical significance of high monocyte counts for the continuous treatment with nintedanib.
1
—
—